Merck related stories
All articles and analysis
Paul Capital in $45m Merck royalty dealJust days after the drug was approved by federal drug authorities, San Francisco-based Paul Capital announced a partial royalty interest in ROTATEQ, a Merck vaccine.
- Upbeat on life sciences
Aisling Capital’s Dennis Purcell believes a change in the dynamics of the pharmaceutical industry spells good fortune for life sciences investors. By Ken MacFadyen.
- Liquid year for Clayton Dubilier
The New York buyout firm has distributed more than $2.5bn to limited partners in 2004.
- CD&R leads year’s largest European LBO
A consortium comprising Clayton Dubilier & Rice, Eurazeo and Merrill Lynch Global Private Equity has signed an exclusive agreement to purchase listed French electrical distributor Rexel for €3.7bn.
- CD&R to buy Culligan from French parent
Clayton Dubilier & Rice, the US-based global investor, says it has reached a definitive agreement to acquire Culligan International from Veolia Environnement of France for $610m.
- CD&R’s London office grows by one
In the wake of two significant European deals, Clayton, Dubilier & Rice has hired former Morgan Stanley Capital Partners managing director Christian Rochat.
- CD&R recaps global IT service provider
Clayton, Dubilier & Rice has agreed to recapitalise publicly held Covansys and exchange its stake in the company for $180 million in cash, as well as stock, notes and warrants.
- CD&R completes $1.65bn VWR deal
Clayton, Dubilier & Rice takes over the laboratory supplies company from pharmaceuticals group Merck, putting $450m of its own equity toward the deal.
- CD&R commits $600m to distribution carve-out
Clayton, Dubilier & Rice has agreed to acquire VWR International, a distributor of laboratory supplies, from pharmaceuticals group Merck in a $1.65bn leveraged carve-out.
- Sykes to take stake in Apax buy-in
Sir Richard Sykes is to become chairman of Medeus, a new company which has acquired the drugs marketing arm of Elan Corporation in a $120m MBI funded by Apax Partners.